Event Details
December 01, 2018
Description
Phase II 100 patient placebo controlled trial for GW's CBDV drug began.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| Gwadar | location | 2 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024909.jpg
Page 93 of a Cowen equity research report dated February 25, 2019. The text details clinical trial results for pharmaceutical companies GW and Zynerba regarding cannabinoid treatments (CBDV and ZYN002) for autism spectrum disorders, epilepsy, and Fragile X syndrome. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was included in a document production for a congressional investigation, though the specific page content is purely technical/medical market research.
Related Events
Events with shared participants
AES 2017 (American Epilepsy Society meeting) where GW presented pooled analysis.
2017-01-01 • N/A
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event